Therapeutic Asset Ratings
414 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Kras Tcr-Transduced Pbl
Colorectal Cancer
National Cancer Institute (NCI)
P2
CCC
(50)
Pirfenidone
Colorectal Cancer
Guoxiang Cai
P2
CCC
(50)
Riluzole
Colorectal Cancer
University of California, Irvine
P2
CCC
(50)
Shr-8068
Colorectal Cancer
Fudan University
P2
CCC
(50)
Tisleizumab
Colorectal Cancer
Tao Zhang
P2
CCC
(50)
Vactosertib
Colorectal Cancer
David Wald
P2
CCC
(50)
Denosumab
Colorectal Cancer
Redx Pharma Ltd
P2
CCC
(48)
Dkn-01
Colorectal Cancer
Leap Therapeutics, Inc.
P2
CCC
(48)
FAPI74
Colorectal Cancer
SOFIE
P2
CCC
(48)
Mycobacterium Obuense
Colorectal Cancer
AIO-Studien-gGmbH
P2
CCC
(48)
Ompenaclid
Colorectal Cancer
Inspirna, Inc.
P2
CCC
(48)
Prolgolimab
Colorectal Cancer
Blokhin's Russian Cancer Research Center
P2
CCC
(48)
rxc004
Colorectal Cancer
Redx Pharma Ltd
P2
CCC
(48)
GEH300079 (68Ga)
Colorectal Cancer
GE Healthcare
P2/3
CCC
(48)
Grt-C903
Colorectal Cancer
National Cancer Institute (NCI)
P1/2
CCC
(48)
Grt-R904
Colorectal Cancer
National Cancer Institute (NCI)
P1/2
CCC
(48)
hr070803
Colorectal Cancer
Jiangsu HengRui Medicine Co., Ltd.
P2/3
CCC
(48)
Jab-21822
Colorectal Cancer
Jian Li
P1/2
CCC
(48)
Osimertinib
Colorectal Cancer
Genentech, Inc.
P1/2
CCC
(48)
Retifanlimab
Colorectal Cancer
National Cancer Institute (NCI)
P1/2
CCC
(48)
Rintatolimod
Colorectal Cancer
Roswell Park Cancer Institute
P2
CC
(47)
Agen1423
Colorectal Cancer
Weill Medical College of Cornell University
P2
CC
(46)
Aguix
Colorectal Cancer
Brigham and Women's Hospital
P2
CC
(46)
Aipalolitovorelizumab
Colorectal Cancer
Yanqiao Zhang
P2
CC
(46)
All Trans Retinoic Acid
Colorectal Cancer
University of Texas Southwestern Medical Center
P2
CC
(46)
Showing 101 to 125 of 414 assets
Previous
Page 5 of 17
Next